The global smart inhalers market size reached USD 303.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,598.2 Million by 2033, exhibiting a growth rate (CAGR) of 19.25% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 303.6 Million |
Market Forecast in 2033
|
USD 1,598.2 Million |
Market Growth Rate 2025-2033 | 19.25% |
Smart inhalers are respiratory inhalers that can monitor adherence, send dosage reminders, offer access to readily shareable information via Bluetooth, and record the time, date and location of each dosage administered accurately. They can also help improve compliance with therapy, increase patient involvement and motivation in controlling symptoms, and provide reports about environmental and weather conditions that may affect their chest. Due to the growing prevalence of asthma and chronic obstructive pulmonary diseases (COPD), there is a rise in the demand for smart inhalers across the globe.
Due to a rise in air pollution levels worldwide, there is a significant increase in the number of patients with chronic respiratory diseases (CRDs), lung cancer, chronic bronchitis, and acute lower respiratory infections (ALRI). This represents one of the key factors propelling the growth of the market. Moreover, the efficacy of conventional inhalers can be negatively impacted by incorrect inhaler techniques and poor adherence, which may result in the progression of patients’ condition. However, smart inhalers can address the challenges of patients and healthcare professionals in the management of these diseases using digital features designed to connect with mobile applications for monitoring medication schedules and subsequent dosing. Additionally, they can alert patients and clinicians when symptoms require specific action and facilitate a shift to better self-care. This, coupled with recent advances in smart inhaler technology, which allow feedback to users on their inhaler technique and the calculation of the correct level of adherence, is driving the market. Besides this, the increasing awareness about the benefits of using smart inhalers among patients is projected to augment the overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global smart inhalers market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
Breakup by Indication:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Adherium Limited, AptarGroup Inc., AstraZeneca plc, Boehringer Ingelheim, Cognita Labs, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG, Teva Pharmaceutical Industries Ltd. and Vectura Group Limited (Philip Morris International Inc.).
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Indication, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | 3M Company, Adherium Limited, AptarGroup Inc., AstraZeneca plc, Boehringer Ingelheim, Cognita Labs, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG, Teva Pharmaceutical Industries Ltd. and Vectura Group Limited (Philip Morris International Inc.). |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global smart inhalers market was valued at USD 303.6 Million in 2024.
We expect the global smart inhalers market to exhibit a CAGR of 19.25% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic has led to growing adoption of smart inhalers to provide an alert to the patients and healthcare professionals for the coronavirus infection symptoms, that require specific action and facilitate a shift to better self-care.
The rising consumer awareness towards numerous associated benefits of smart inhalers in monitoring adherence, sending regular dosage reminders, offering access to readily shareable information via Bluetooth, etc., is primarily driving the global smart inhalers market.
Based on the product, the global smart inhalers market can be segmented into inhalers and nebulizers. Currently, inhalers hold the majority of the total market share.
Based on the indication, the global smart inhalers market has been divided into asthma and Chronic Obstructive Pulmonary Disease (COPD), where asthma currently exhibits a clear dominance in the market.
Based on the distribution channel, the global smart inhalers market can be categorized into hospital pharmacies, retail pharmacies, and online stores. Among these, hospital pharmacies account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global smart inhalers market include 3M Company, Adherium Limited, AptarGroup Inc., AstraZeneca plc, Boehringer Ingelheim, Cognita Labs, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG, Teva Pharmaceutical Industries Ltd., and Vectura Group Limited (Philip Morris International Inc.).